enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
7.48
-1.20 (-13.82%)
Mar 9, 2026, 2:55 PM EDT - Market open
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC).
Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.
enGene Holdings Inc.
| Country | Canada |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Ronald H. Cooper |
Contact Details
Address: 4868 Rue Levy, Suite 220 Montreal, QC H4R 2P1 Canada | |
| Phone | 514 332 4888 |
| Website | engene.com |
Stock Details
| Ticker Symbol | ENGN |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001980845 |
| CUSIP Number | 46429B226 |
| ISIN Number | CA29286M1059 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald H. W. Cooper | President, Chief Executive Officer and Director |
| David Ryan Daws | Chief Financial Officer and Head of Business Development |
| Dr. Hussein Sweiti M.D., M.Sc. | Chief Medical Officer and Head of Research and Development |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Alexander Nichols Ph.D. | Chief Strategy and Operations Officer |
| Joan Connolly | Chief Technology Officer |
| Lee G. Giguere | Chief Legal Officer and Corporate Secretary |
| Tara Place M.B.A. | Senior Vice President of Human Resources |
| Matthew Boyd | Chief Regulatory Officer |
| Jill Buck | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 9, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 9, 2026 | 424B5 | Filing |
| Mar 9, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 10-Q | Quarterly Report |
| Mar 9, 2026 | 8-K | Current Report |
| Mar 2, 2026 | EFFECT | Notice of Effectiveness |
| Feb 19, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 19, 2026 | 10-K/A | [Amend] Annual report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |